Background and Aims: Pregnancy guidelines for women with inflammatory bowel disease [IBD] provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit foetal exposure. Although infliximab [IFX] leads to higher anti-TNF concentrations in cord blood than adalimumab [ADA], the recommendations are similar. We aimed to demonstrate the effect of anti-TNF cessation during pregnancy on foetal exposure, for IFX and ADA separately. Methods: We conducted a prospective single-center cohort study. Women with IBD, using IFX or ADA, were followed-up during pregnancy. In case of sustained disease remission, anti-TNF was stopped in the third trimester. At the birth, the anti-TNF concentration was measured in the cord blood. A linear regression model was developed to demonstrate anti-TNF concentration in cord blood at birth. In addition, outcomes such as disease activity, pregnancy outcomes and 1-year health outcomes of infants were collected. Results: We included 131 pregnancies that resulted in a live birth [73 IFX, 58 ADA]. At birth, 94 cord blood samples were obtained [52 IFX, 42 ADA], showing significantly higher levels of IFX than ADA [p < 0.0001]. Anti-TNF type and stop week were used in the linear regression model. During the third trimester, IFX transportation over the placenta increased exponentially; however, ADA transportation was limited and increased in a linear fashion. Overall, health outcomes were comparable. Conclusions: Our linear regression model shows that ADA may be continued longer during pregnancy, because transportation over the placenta is lower than for IFX. This may reduce relapse risk of the mother, without increasing foetal anti-TNF exposure.
Introduction
Active inflammatory bowel disease [IBD] during conception and pregnancy has been associated with adverse pregnancy outcomes such as spontaneous abortion, intrauterine growth restriction, preterm birth and low birth weight. [1] [2] [3] [4] Current pregnancy guidelines therefore advise conception during a time of disease remission. 5, 6 In order to maintain disease remission, anti-TNF IgG1 monoclonal antibodies such as infliximab [IFX] and adalimumab [ADA] are increasingly being used. These drugs, however, are actively transported over the placenta to the foetus. 7, 8 The transportation of IgG1 antibodies over the placenta increases exponentially during the third trimester, resulting in higher foetal levels than maternal levels at term. [9] [10] [11] Previous studies among women suffering from IBD have suggested that the use of IFX and ADA during pregnancy is not related to adverse pregnancy outcomes, nor to adverse health outcomes of children until 1 year of age. [12] [13] [14] [15] [16] [17] However, a case series reported severe neutropenia at birth in four IFX-exposed children 18 ; also, a case of a fatal disseminated Bacille Calmette-Guerin [BCG] infection of an IFX-exposed child has been reported. 19 In addition, an increased infection risk has been seen in children exposed in utero to a combination of an immunomodulator and either IFX or ADA, 20, 21 and it should be noted that long-term health outcomes of anti-TNFexposed infants have scarcely been studied. In view of this data, the safety of in utero exposure to high levels of anti-TNF is difficult to take for granted and should preferably be avoided.
Current pregnancy guidelines provide recommendations on how to balance the limiting of drug exposure in utero to avoid health risks for the foetus with maintaining maternal disease remission. If women are not in sustained disease remission, it is advised to continue anti-TNF treatment throughout the entire pregnancy, because active IBD increases the risk of adverse pregnancy outcomes. However, in the case of women in sustained disease remission, anti-TNF treatment cessation may be considered in the third trimester to minimize foetal drug exposure. Anti-TNF cessation in the third trimester seems feasible in this latter group because it does not lead to an increased relapse risk. 17 These current pregnancy guidelines, however, do not differentiate between IFX and ADA, although different pharmacokinetics are expected. A recent study, comparing anti-TNF levels in cord blood and the time of infant drug clearance between IFX-exposed infants and ADA-exposed infants, found significantly higher anti-TNF levels in cord blood and a longer time to anti-TNF clearance in IFXexposed infants than in ADA-exposed infants. 20 This suggests that it may be possible to extend ADA treatment longer during the third trimester of pregnancy than IFX treatment, without increasing anti-TNF levels in the newborn.
The primary aim of our study was to illustrate the effect of gestational anti-TNF cessation on foetal drug exposure in a linear regression model for IFX and ADA separately. The secondary aims were to assess disease course during pregnancy, birth outcomes, adverse events after anti-TNF re-initiation, and infants' health outcomes at 1 year for IFX and ADA separately.
Material and Methods

Study design
All IBD women treated with either IFX or ADA who visited the preconception outpatient clinic at the Erasmus University Medical Center Rotterdam, a tertiary health centre, from December 2008 through June 2016 were prospectively enrolled. If patients did not attend follow-up visits at our clinic and/or if the pregnancy outcomes could not be retraced, they were excluded from analyses. This cohort consisted partly of women from a previously published cohort 17 and partly of additional follow-up information. During visits at our IBD outpatient clinic, patients were counselled before pregnancy and seen bi-monthly during pregnancy by an experienced IBD physician. In case of disease activity, women were seen every second week at the outpatient clinic. Patients were counselled on medication use, folic acid intake, life style habits [e.g. smoking, alcohol use] and the importance of achieving and maintaining disease remission before conception and during pregnancy. Data regarding disease activity, medication adherence, smoking, alcohol use, folic acid intake and obstetric complications were collected during each visit. Disease activity was assessed based on clinical symptoms. (Harvey Bradshaw Index [HBI] or Simplified Clinical Colitis Activity Index [SCCAI], blood analysis, fecal calprotectin [FCP] measurement and an endoscopy was performed when necessary.) In case of disease relapse at any time from 6 months before conception until Gestational Week 20, anti-TNF treatment would be continued during the entire pregnancy. In case of sustained disease remission from 6 months before conception until Gestational Week 20, the option of discontinuing anti-TNF treatment in the third trimester was discussed in a multidisciplinary team, including the gynaecologist and the patient. All patients were additionally informed by an experienced IBD nurse regarding anti-TNF measurements in cord blood and peripheral maternal blood at birth. During this consult, patients received written instructions on how to obtain the blood samples at birth, which they handed over to their gynaecologist. During delivery, blood samples were collected by the gynaecologist and sent directly to the Laboratory of Gastroenterology at the Erasmus University Medical Center.
Birth outcomes such as gestational age at birth, birth weight, and the presence of congenital abnormalities were noted during the first visit after delivery. After 1 year, health outcomes from infants were obtained through telephonic questionnaire with mothers and/or by obtaining medical information from the general practitioner after the consent of both parents. The 1-year outcomes included growth, infections for which systemic antibiotic treatment were needed, hospitalization for an infection, allergies, chronic diseases, adverse reactions to vaccinations, and the presence of eczema.
Outcome measurements
Anti-TNF serum level measurements were performed since 2010 at our clinic. These measurements were done by ELISA from peripheral blood, as described in previous papers. 
Definitions
Abnormal growth is defined as a growth or height for age and gender deviating >2 standard deviations [SD] from the mean Dutch growth chart. Preterm birth is defined as a delivery before 37 weeks of gestation. Small for gestational age [SGA] is a weight below the 2 SD for gestational age according to the Dutch reference curve. 23 The presence of disease activity was assessed by the treating physician and based on the combination of clinical symptoms [HBI > 5 or SCCAI > 2], C-reactive protein [CRP] > 9.0 mgL, FCP measurement > 200 µg/g and when strongly indicated, an endoscopy was performed. The standard dose of anti-TNF treatment is 5 mg/kg intravenously every 8 weeks for IFX and 40 mg subcutaneously every 2 weeks for ADA.
Study size
The primary aim was to assess the difference in anti-TNF cord blood concentrations between IFX and ADA and subsequently use the anti-TNF cord blood concentrations as a dependent variable in a linear regression model. The null hypothesis assumed no difference in anti-TNF cord blood concentration between IFX users and ADA users. We used the median anti-TNF level in cord blood and the range from a previous study 20 and estimated the mean and SD according to the method devised by Hozo et al. 24 We expected the mean anti-TNF concentration of ADA users to be lower than the mean anti-TNF concentration of IFX users; therefore, a one-sided test with alpha of 2.5% was used. To detect a lower mean anti-TNF concentration in cord blood of 3.5 µg/mL in ADA users, with a power of 90%, the estimated sample size was 31 per arm. [CI] . Anti-TNF cord blood data was normalized by log transformation. Simple linear regression analyses were performed to determine the association between variables and anti-TNF concentration in cord blood at birth. All possible predictors [i.e. maternal age, diagnosis, pre-pregnancy body mass index [BMI], prepregnancy weight, anti-TNF stop week, smoking, type of anti-TNF, thiopurine use, steroid use, gestational age at birth, birth weight, bowel resection prior to pregnancy, anti-TNF dose, and disease relapse during pregnancy] were considered. Subsequently, only variables with a p-value < 0.20 in the univariate analysis and variables based on clinician's rationale [i.e. disease activity during pregnancy, anti-TNF dose, and concomitant thiopurine use] were considered for the multiple linear regression model. These variables were carefully weighted to create the most favorable model. In the final multivariate model, interactions were tested between the independent variables and were included when significant [p < 0.01].
Statistical considerations
Ethical statement
This study was approved by the local ethics committee of the Erasmus University Medical Center [Rotterdam, The Netherlands]. Legal guardians of the children signed informed consent before data was collected from the general practitioner. [56%] infants were exposed to IFX and 60 [44%] were exposed to ADA in utero. There were 5 women who stopped anti-TNF treatment before the second trimester [3 IFX, 2 ADA], which was advised by a physician other than a gastroenterologist. These women were excluded from further analyses. Baseline characteristics per pregnancy are shown in Table 1 . In our cohort, women with CD more often used ADA, and women with UC more often used IFX. In addition, IFX was more often prescribed in the case of extensive CD and in combination with a thiopurine. There were no other differences in the baseline characteristics between IFX users and ADA users.
Results
A total of
Maternal outcomes
Maternal outcomes are displayed in Table 2 . There were no differences regarding weight gain during pregnancy, anti-TNF stop week, disease relapse during pregnancy, or successful treatment of the relapse between IFX users and ADA users. In addition, we observed no differences in adverse events after restarting anti-TNF post-partum, such as allergic reactions, loss of response, or disease relapse within 3 months post-partum between these groups. 
Disease relapse
Pregnancy outcomes
No differences were observed in terms of birth weight, gestational age at birth, the presence of congenital abnormalities, or mode of delivery between IFX-exposed infants and ADA-exposed infants [ Table 2 ]. Three children were born with a congenital abnormality. Two of the 3 mothers did not use folic acid at the time of conception. In addition, the mother of the child born with a polydactyly used methotrexate at the time of conception. She stopped the methotrexate and started folic acid after she discovered her pregnancy. The other mothers did not use teratogenic medication.
Drug concentration in cord blood and maternal blood
At birth, cord blood samples in which anti-TNF concentration was measured were obtained from 94 mothers; 52 used IFX and 42 used ADA during pregnancy. The results are shown in Table 3 . Anti-TNF levels in cord blood, and the ratio of cord blood level / maternal level were both higher in IFX users than in ADA users. In addition, anti-TNF levels in maternal blood were higher in IFX users than in ADA users [p = 0.05]. There were no other differences between women using IFX and women using ADA regarding anti-TNF stop week during pregnancy, duration of anti-TNF treatment before conception, relapse rate, or number of women using the standard dose.
Linear regression model
The simple linear regression analyses, assessing the association between variables and anti-TNF concentration in cord blood at birth, are shown in Table 4 . Only the variables anti-TNF stop week and type of anti-TNF were strongly associated with anti-TNF concentration in cord blood. There was no significant correlation between these two variables. No other variables improved the model. Therefore, in the final multiple linear regression model, anti-TNF stop week and type of anti-TNF were used as independent variables, and anti-TNF cord blood concentration at birth as a dependent variable [ Figure 1 ]. This model shows that IFX transportation over the placenta increases exponentially during the third trimester of pregnancy. However, ADA transportation over the placenta is significantly lower than IFX and increases in a linear fashion.
One-year health outcomes of infants exposed to anti-TNF in utero
Out of all live births, health outcomes until 1 year of age were obtained from 93 infants [71%] . These results are shown separately [ Table 5 ]. Information was not obtained if infants did not yet reach the age of 1, or if we were unable to contact the mother for a telephonic questionnaire. There were no differences regarding growth, infection rate, hospitalization because of an infection, allergies, chronic diseases, adverse reactions to vaccinations, or the presence of eczema between IFX-exposed infants and ADAexposed infants.
Growth
There were 2 infants [2%] with an abnormal growth [1 IFX, 1 ADA]. One infant, diagnosed with cystic fibrosis [CF], had a primary growth failure. The second infant had a secondary growth failure; however, the cause was still unknown at the time of analyses.
Infections
In total, 25 infants [27%] received one or more antibiotic treatments in the first year of life, of whom 12 [48%] were exposed to IFX. None of the infants received more than three antibiotic treatments. Anti-TNF type was not associated with the number of antibiotic-treated infections. A total of 33 oral antibiotic treatments were prescribed for . There was no statistically significant difference regarding anti-TNF cord blood level between children without antibiotictreated infections, children with one antibiotic-treated infection, and children with two or more antibiotic-treated infections.
The rate of children who received at least one antibiotic treatment was similar for infants who were exposed to combination There were four children exposed to IFX [50%]. The median cord blood level at birth of children admitted to hospital was 3.5 µg/ mL [IQR 0.3-8.9], and the median cord blood level at birth of children not admitted to hospital was 2.0 µg/mL [IQR 0.9-7.8]. There was no statistically significant difference regarding anti-TNF cord blood level between children admitted to hospital and children not admitted to hospital because of an infection in the first year of life [p = 0.87].
There was no difference in hospital admission rate between anti-TNF types. Furthermore, there was no difference in hospital admissions because of a severe infection between infants exposed to combination therapy [n = 2, 8%] and infants exposed to anti-TNF monotherapy [n = 6, 9%] [p = 1.00].
Allergies
Eight infants [9%] suffered from an allergy, of which three [38%] were exposed to IFX and five [62%] to ADA. The following types of allergies were reported: cow milk allergy [n = 4], antibiotics [n = 2], allergic rhinitis [n = 1], and a sun allergy that resolved completely shortly after diagnosis [n = 1]. There was no correlation between anti-TNF type and allergies.
Adverse reaction to vaccinations
Life vaccinations were avoided in cases in which anti-TNF levels were >3 µg/mL in the offspring. In The Netherlands, the first life vaccination is administered at the age of 14 months. None of the infants had anti-TNF levels >3 µg/mL at 14 months of age; moreover, none of the infants had anti-TNF levels exceeding 1 µg/mL at 6 months of age. Furthermore, none of the infants in our cohort had an adverse reaction to a vaccination.
Discussion
We developed a linear regression model to demonstrate the effect of anti-TNF cessation during pregnancy on foetal exposure, for IFX and ADA separately. Anti-TNF concentrations in cord blood and maternal blood were higher in the IFX group than in the ADA group. Our linear regression shows that IFX transportation over the placenta increases exponentially during the third trimester of pregnancy. However, ADA transportation over the placenta is lower and increases in a linear fashion. Therefore, ADA may be continued longer during pregnancy than IFX without leading to higher anti-TNF concentrations in the newborn. In cases of disease activity in women with a current or future pregnancy, and in pregnant women who need to step-up to anti-TNF therapy, ADA may therefore be preferred over IFX. Furthermore, we did not observe significant differences in disease course, maternal outcomes, or birth outcomes between women using IFX and women using ADA during pregnancy.
Continuing ADA longer during pregnancy may avoid low maternal ADA levels and subsequently an increased relapse risk in mothers. In addition, a shorter anti-TNF drug holiday may reduce the risk of an adverse event after drug re-initiation, such as an allergic reaction, or loss of response. We did not observe significant differences between the anti-TNF types regarding relapse rate or adverse events after drug re-initiation. However, our study may be underpowered, and therefore further evaluation in larger prospective studies is needed.
Anti-TNF concentrations in cord blood varied widely between individuals, as is the case in non-pregnant patients. 22, 25 This variation is possibly due to several factors influencing the pharmacokinetics of anti-TNF drugs, such as anti-drug antibody formation, concomitant immunosuppressive therapy, serum CRP concentration, BMI, and serum albumin concentration. 22, 26, 27 In addition, physiological changes during pregnancy may also alter the pharmacokinetics of anti-TNF drugs. The latter was demonstrated in a recent study showing a significant increase in the maternal anti-TNF level during pregnancy in women using IFX with a fixed dosing schedule, irrespective of albumin level or BMI. 28 The underlying mechanism for this finding remains unknown and needs further evaluation.
Because of the relatively small sample size, this study may be underpowered to demonstrate an association between potential predictor variables and anti-TNF concentration in cord blood. However, despite the small sample size, we did find a very strong association between anti-TNF concentration in cord blood and the variables anti-TNF type and stop week. These robust findings indicate that these variables are of utmost importance when predicting anti-TNF concentration in cord blood, which underlines the large pharmacokinetic differences between IFX and ADA.
One-year health outcomes, such as growth, infection rate, hospitalization because of an infection, allergies, chronic diseases, adverse reactions to vaccinations, and the presence of eczema were similar between IFX-exposed and ADA-exposed infants. One or more infections were documented in 31% of infants, which is in line with a non-controlled follow-up study assessing the health outcomes of 25 anti-TNF-exposed children, of whom 32% were treated for an infection in the first year of life. 29 The infection rate in our cohort is also in line with that of the overall Dutch population. 30 However, the infection rate was higher in infants from non-IBD controls from the same geographic region, namely 40%. 17 It should be noted that infection data are biased because parents of infants with a cord blood concentration of 3 µg/mL or higher were advised not to bring their child to day-care, to be extra cautious of infectious sources, and to postpone all life vaccinations before the repeated anti-TNF measurement was below 3 µg/mL. Therefore, the actual infection risk in the first year in anti-TNF-exposed infants may be higher than shown in our study. The cut-off level of 3µg/mL is, however, arbitrary and was initially based on adult studies showing an association between an IFX level of >3µg/mL and response to treatment. 31 Subsequent studies showed that higher trough levels may be needed for response in the case of ADA treatment. However, we conservatively continued to use the lower cut-off value, based on the pharmacokinetics of IFX, in order to minimize health risks for the newborns. It should be noted that this cohort received stringent counselling and follow-up before and during pregnancy. This strict follow-up has a beneficial effect on pregnancy outcomes and should be taken into account when comparing the results with those of other studies. In addition, disease activity during pregnancy could not be assessed in a standard manner. During pregnancy, some clinical scores and laboratory work-up are of limited value. Pregnant women often experience abdominal complaints, regardless of their underlying IBD, and clinical scores such as hematocrit and body weight to assess disease activity are of little value because pregnant women often become anemic and most women gain weight during pregnancy. An endoscopy to assess disease activity was only performed in cases where there was a strong indication. Furthermore, cord blood samples were not obtained from all pregnancies because anti-TNF measurements have only been performed since 2010 at our clinic, and there were samples missing because of logistic problems; however, missing samples were missing at random. In addition, we did not find a correlation between anti-TNF cord blood levels and the impact on the developing immune system of the child. However, this study may be underpowered to demonstrate a correlation, and therefore further prospective studies on this topic are needed.
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In conclusion, ADA may be continued longer during pregnancy than IFX because of the lower placental transmission. Continuing ADA longer during pregnancy may reduce relapse risk of the mother without increasing foetal anti-TNF exposure.
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